Profile
International Journal of Gastroenterology Disorders & Therapy Volume 4 (2017), Article ID 4:IJGDT-129, 6 pages
https://doi.org/10.15344/2393-8498/2017/129
Research Article
A Potential Asset of Proteasome Inhibitor Singly or Combined with Cisplatin Provides Inhibitory Effect on Human Gastric Cancer Cells

Jie Jin1, Zhenzhen Li2, Honghua Ding2 and Dadao Jing2,*

1Department of Gastroenterology, Branch of Shanghai General Hospital, Shanghai, China
2Department of Geriatrics and Gastroenterology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China
Dr. Dadao Jing, Department of Geriatrics and Gastroenterology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China; E-mail: dadaojing@126.com
17 February 2017; 09 August 2017; 11 August 2017
Jin J, Li Z, Ding H, Jing D (2017) A Potential Asset of Proteasome Inhibitor Singly or Combined with Cisplatin Provides Inhibitory Effect on Human Gastric Cancer Cells. Int J Gastroenterol Disord Ther 4: 129. doi: http://dx.doi.org/10.15344/2393-8498/2017/129

Abstract

Backgrounds and Objective: Proteasome inhibitors are a kind of novel anti-tumor agent which can inhibit cell growth and induce apoptosis by inhibiting the function of proteasome system and impacting the degradation of proteins related to cell growth or apoptosis. The aim of the study is to explore the effect of proteasome inhibitor Z-Leu-Leu-Phe-CHO (ZLLFC) singly or combined with cisplatin on proliferation or apoptosis of humnan gastric cancer cell SGC-7901, as well as its influence on the expression level of excision repair cross complementing 1(ERCC1) mRNA.
Methods: MTT assay was used to calculate the growth inhibitory rate of human gastric cancer cell SGC- 7901. The apoptotic cell morphology was observed with electron microscopy, the apoptotic rate was analyzed by flow cytometry and by expression level of ERCC1 mRNA detected by RT-PCR.
Results: Proteasome inhibitor ZLLFC could inhibit the growth of gastric cancer cell SGC-7901. Combined application of proteasome inhibitor ZLLFC and cisplatin significantly increase the inhibitory effect on SGC-7901 cells, induced apoptosis and increased the apoptotic rate. While, the expression level of ERCC-1 mRNA in SGC-7901 cells in the combined group was significantly lower than that of the cisplatin group (p<0.01).
Conclusion: Proteasome inhibitor ZLLFC can inhibit the growth of gastric cancer cell SGC-7901. Combined application of ZLLFC and cisplatin can significantly increase the growth inhibiory effect and the apoptosis-promoting effect of gastric cancer cell SGC-7901.